Search results
Results from the WOW.Com Content Network
Solriamfetol is used to promote wakefulness in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. [1] It appears to be more effective in improving excessive daytime sleepiness associated with obstructive sleep apnea than certain other wakefulness-promoting agents including modafinil, armodafinil, and pitolisant.
Chemical structure of modafinil.. This page lists chemical compounds similar to modafinil, known as modafinil analogues and derivatives.These are structural analogues and derivatives of modafinil, a drug that affects dopamine levels in the brain in an unusual way (atypical dopamine reuptake inhibitor or DRI).
At steady state, the systemic exposure for armodafinil is 1.8 times the exposure observed after a single dose. The concentration-time profiles of the (R)-(−)-enantiomer following a single dose of 50 mg Nuvigil or 100 mg Provigil (modafinil being a 1:1 mixture of (R)-(−)- and (S)-(−)- enantiomers
Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in very similar pharmacological effects. [6] Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45–60 minutes when taken orally on an empty stomach. [citation needed]
Modafinil is generally well-tolerated but can have potential risks and side effects. Common adverse effects of modafinil, experienced by less than 10% of users, include headaches, nausea, and reduced appetite. [93] [94] [20] Anxiety, insomnia, dizziness, diarrhea, and rhinitis are also reported in 5% to 10% of users. [20]
Eugeroics, in the sense of modafinil-type wakefulness promoting agents, include modafinil itself, armodafinil, and adrafinil, among others. [9] They are medically indicated for the treatment of certain sleep disorders , including excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA).
Unlike armodafinil ((R)-(–)-modafinil), esmodafinil has never been marketed on its own. [ 3 ] Esmodafinil is suspected to be less clinically useful for treating conditions that modafinil and armodafinil are marketed for, such as narcolepsy , shift work sleep disorder , and obstructive sleep apnea .
Modafinil and its analogues are known to act as dopamine reuptake inhibitors and this is thought to be involved in their wakefulness-promoting effects. [1] Chemically , fladrafinil is a derivative of adrafinil ( N -hydroxymodafinil) and is also known as bisfluoroadrafinil (it is the bis (4- fluoro ) phenyl ring - substituted derivative of ...